The FDA assessed the safety and performance of atidarsagene autotemcel determined by knowledge from 37 little ones who received atidarsagene autotemcel in two solitary-arm, open up-label scientific trials As well as in an expanded accessibility method.[seven] Children who obtained cure with atidarsa